Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TK1 | P04183 | 2/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15740192 | 1.00 | DNMT1 (0.60) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL29070733 | 1.00 | DNMT1 (0.60) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5982159 | 1.00 | DNMT1 (0.60) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL6906161 | 1.00 | DNMT1 (0.60) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5982164 | 1.00 | DNMT1 (0.60) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5983326 | 0.89 | DNMT1 (0.60) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5983324 | 0.89 | DNMT1 (0.60) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL13293701 | 0.88 | DNMT1 (0.45) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL10015665 | 0.87 | DNMT1 (0.53) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL25492471 | 0.87 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612662-B2 | DNA repair site detection for personal genomics, epigenomics, and gene therapy | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2026-04-28 | — | — | US | claimed |
| US-20240254545-A1 | SPATIOTEMPORALLY RESOLVED TRANSCRIPTOMICS AT SUBCELLULAR RESOLUTION | THE BROAD INSTITUTE, INC. (US) | 2024-08-01 | — | — | US | claimed |
| EP-4334471-A1 | SPATIOTEMPORALLY RESOLVED TRANSCRIPTOMICS AT SUBCELLULAR RESOLUTION | The Broad Institute Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| CN-117616135-A | Subcellular resolution space-time resolved transcriptome | 布罗德研究所股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| US-20230111083-A1 | DNA REPAIR SITE DETECTION FOR PERSONAL GENOMICS, EPIGENOMICS, AND GENE THERAPY | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2023-04-13 | — | — | US | claimed |
| WO-2022236011-A1 | SPATIOTEMPORALLY RESOLVED TRANSCRIPTOMICS AT SUBCELLULAR RESOLUTION | THE BROAD INSTITUTE, INC. (US) | 2022-11-10 | — | — | WO | claimed |
| WO-2021194531-A1 | DNA REPAIR SITE DETECTION FOR PERSONAL GENOMICS, EPIGENOMICS, AND GENE THERAPY | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-09-30 | — | — | WO | claimed |
| CN-111201327-A | Method for detecting one or more DNA ends and uses thereof | 音图基因公司 | 2020-05-26 | — | — | CN | claimed |
| EP-3186387-B1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | UNIV PALACKEHO (CZ) | 2018-10-17 | — | — | EP | claimed |
| EP-3186387-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | Univerzita Palackého v Olomouci (CZ) | 2017-07-05 | — | — | EP | claimed |
| WO-2016029889-A1 | METHOD OF DETERMINING THE ACTIVITY OF ENZYMES CONVERTING CYTOSINE DERIVATIVES TO URACIL DERIVATIVES IN CELLS, TISSUES AND ORGANISMS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-03-03 | — | — | WO | claimed |
| EP-0923596-A2 | LIPOPHILIC OLIGONUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1999-06-23 | — | — | EP | claimed |
| US-5763208-A | Oligonucleotides and their analogs capable of passive cell membrane permeation | GILEAD SCIENCES, INC. (US) | 1998-06-09 | — | — | US | claimed |
| WO-1998004575-A2 | LIPOPHILIC OLIGONUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | claimed |
| US-5633360-A | CONTAINS AT LEAST TWO NUCLEOSIDE RESIDUES AND INTERNUCLEOTIDE LINKAGES | GILEAD SCIENCES, INC. (US) | 1997-05-27 | — | — | US | claimed |
| EP-0573479-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-12-15 | — | — | EP | claimed |
| WO-1992015693-A1 | CHIMERIC TAR ENZYME CONSTRUCTION FOR HIV THERAPY | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-09-17 | — | — | WO | claimed |
| US-12612662-B2 | DNA repair site detection for personal genomics, epigenomics, and gene therapy | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2026-04-28 | — | — | US | disclosed |
| EP-0417560-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
| EP-0272065-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612662-B2 | DNA repair site detection for personal genomics, epigenomics, and gene therapy | OGG1, BRCA1, TNNC1 | DNMT1 7/4885ADRB1 2522/4885DNMT3B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.